United States Patent 6,126,920: Claim Scope, Expiration, Orange Book Status, and Patent Landscape

U.S. Patent No. 6,126,920 covers topical treatment methods using a quick-break corticosteroid foam with alcohol, fatty alcohol, surfactant, propellant, and a pH-control system. The claims are directed primarily to the formulation and its therapeutic use, with dependent claims narrowing the invention to betamethasone valerate, ethanol, cetyl-stearyl alcohol, citrate buffering, and scalp psoriasis.

The patent is associated with the betamethasone valerate foam product Luxiq. Its patent term has expired, removing the patent as a current U.S. barrier to abbreviated new drug application, or ANDA, approval. The claims remain relevant for historical freedom-to-operate analysis, invalidity review, prior-art mapping, and assessment of later formulation patents. (U.S. Patent No. 6,126,920, 2000; FDA, Approved Drug Products with Therapeutic Equivalence Evaluations, current and historical editions.)

What does U.S. Patent 6,126,920 cover?

The patent covers a method of treating corticosteroid-responsive skin disease by applying a foamable pharmaceutical composition topically. The independent claims require a combination of therapeutic, formulation, and processing characteristics.

Claim element	Claim 1 requirement	Commercial significance
Therapeutic use	Treatment of a skin disease responsive to corticosteroids	Limits the claim to a therapeutic method rather than an unrestricted composition
Dosage form	Foamable pharmaceutical composition	Targets aerosol or propellant-generated topical foam
Active ingredient	Corticosteroid active substance	Broad genus covering numerous topical corticosteroids
Quick-break system	Aliphatic alcohol, water, fatty alcohol, and surface-active agent	Defines the foam vehicle and its rapid collapse on skin
Propellant	Required	Supports aerosol delivery
pH	Buffer sufficient to provide pH of 3.0 to 6.0	Controls stability and formulation performance
Administration	Topical administration to a patient in need	Requires a treatment step

Claim 4 is a separate independent method claim. It requires an active isomer of an isomeric corticosteroid and a buffer that stabilizes the active isomer against conversion to a less active isomer. Unlike claim 1, claim 4 does not expressly recite the pH range of 3.0 to 6.0.

The claims use “comprising,” which generally permits additional ingredients and process steps. A competing product could therefore contain excipients not listed in the claims and still fall within the claim scope if every required limitation is present.

Which claims are broadest and which claims are commercially important?

Claims 1 and 4 are the principal independent claims. Claim 1 is the broader and more operationally defined claim because it expressly requires the pH range and identifies the foam system. Claim 4 focuses on isomer stabilization and may apply where the active corticosteroid exists in stereoisomeric or configurational forms.

Claims 2 and 3 narrow the disease indication:

Claim 2 covers eczema, infantile eczema, atopic dermatitis, dermatitis herpetiformis, contact dermatitis, seborrheic dermatitis, neurodermatitis, psoriasis, and intertrigo.
Claim 3 narrows claim 2 to scalp psoriasis in human subjects.

Claims 5 through 14 narrow the composition by concentration and ingredient identity. Claim 15 recites a specific betamethasone valerate foam formulation.

The most commercially important limitations are likely:

Betamethasone valerate under claim 7.
Ethanol under claim 9.
Cetyl alcohol and stearyl alcohol under claim 11.
Citrate buffering under claim 14.
The formulation in claim 15.
Treatment of scalp psoriasis under claim 3.

A product containing betamethasone valerate foam does not automatically infringe claim 15. It would need to satisfy the specific quantitative formulation limitations in that claim, including the listed percentages or legally equivalent formulation parameters.

What formulation is claimed in claim 15?

Claim 15 recites the following composition:

Ingredient	Amount, % w/w
Betamethasone valerate	0.120
Cetyl alcohol	1.100
Octadecan-1-ol, stearyl alcohol	0.500
Polysorbate 60	0.400
Ethanol	57.790
Purified water	33.690
Propylene glycol	2.000
Anhydrous citric acid	0.073
Potassium citrate	0.027
Butane/propane	4.300
Total	100.000

The formulation contains 0.12% betamethasone valerate, matching the strength associated with Luxiq foam. The vehicle is high in ethanol, uses cetyl and stearyl alcohol as fatty alcohols, and uses a citrate system for pH control.

Claim 15 is narrower than claims 1 and 7. A competing formulation could avoid literal infringement by changing one or more quantitative components, substituting a different buffering system, using a different fatty alcohol ratio, or selecting a different propellant. Whether such changes avoid infringement would depend on the claim language, prosecution history, and possible application of the doctrine of equivalents.

How does claim 4 protect corticosteroid isomer stability?

Claim 4 targets an active isomer that is susceptible to conversion into a less active isomer. Its central limitation is the use of a buffer in an amount effective to stabilize the active isomer.

This claim creates several legal and technical questions:

Whether the corticosteroid is genuinely “isomeric” for purposes of the claim.
Whether the product contains the active isomer in a measurable form.
Whether the buffer has the claimed stabilizing effect.
Whether the less active isomer is formed under relevant storage or use conditions.
Whether the claim requires proof of actual stabilization in the accused product or only a formulation capable of producing that result.

The claim is potentially broader than a claim limited to a named corticosteroid, but it may be more vulnerable to enablement, written-description, indefiniteness, or anticipation arguments if the patent does not adequately support the full range of active isomers and buffer systems.

When did U.S. Patent 6,126,920 expire?

U.S. Patent No. 6,126,920 issued on October 3, 2000. Public patent-term and Orange Book records associate the patent with an expiration date in 2017, commonly reported as March 13, 2017. The relevant term was calculated under the post-1995 patent-term regime, subject to any applicable patent-term adjustment or extension. (U.S. Patent and Trademark Office, Patent Center; FDA, Orange Book.)

The practical result is that the patent is no longer an enforceable U.S. patent. A historical Orange Book listing does not revive an expired patent or prevent a current generic launch.

Event	Date or period
U.S. patent application filing	1997 public-record filing history
Patent issued	October 3, 2000
Associated product	Betamethasone valerate 0.12% foam, marketed as Luxiq
Reported patent expiration	March 13, 2017
Current enforceability	Expired

The exact term should be confirmed against the USPTO patent-term calculation and the relevant Orange Book edition for a litigation-grade opinion. The expiration conclusion, however, is not dependent on the patent’s historical commercial importance.

What was the Orange Book status of Patent 6,126,920?

The patent was associated with Luxiq, a topical betamethasone valerate aerosol foam product. Orange Book listings for approved small-molecule products can include patents claiming the drug substance, formulation, or approved method of use. This patent was principally relevant as a formulation and method-of-use patent rather than as a basic composition-of-matter patent for betamethasone valerate.

The patent’s significance under the Hatch-Waxman framework was that an ANDA applicant could have been required to address the listed patent through:

Paragraph III certification, accepting delayed approval until patent expiration.
Paragraph IV certification, asserting that the patent was invalid, unenforceable, or not infringed.
A statement that the patent was not applicable to the proposed product or indication, depending on the Orange Book listing and ANDA strategy.

Because the patent has expired, it no longer creates a current Paragraph IV launch risk. Historical Paragraph IV litigation may remain relevant to generic entry chronology and settlement analysis, but it does not create present patent exclusivity.

Which companies challenged the Luxiq patent?

The public commercial record connects the patent to the Luxiq betamethasone valerate foam franchise and to generic-drug competition after patent expiry. Historical ANDA applicants may have used Paragraph IV certifications or other patent certifications, but the supplied information does not establish a complete, verified list of challengers, case numbers, filing dates, or settlement terms.

A definitive challenger analysis must distinguish among:

An ANDA applicant that submitted a Paragraph IV certification.
A defendant named in patent litigation.
A company that received tentative approval.
A company that received final approval.
A company that actually launched a generic product.

Those categories are not interchangeable. FDA approval records and federal court dockets are required to identify the complete historical challenger set and determine whether any settlement included a licensed entry date, no-authorized-generic provision, supply agreement, or other commercial restriction.

What patent litigation affected U.S. Patent 6,126,920?

The patent’s litigation relevance arose from the generic-drug pathway for betamethasone valerate foam. A Paragraph IV certification could trigger a 45-day period for the patent owner to file an infringement action and, if timely filed, a statutory stay of ANDA approval for up to 30 months under 21 U.S.C. § 355(j)(5)(B)(iii).

The principal litigation issues would have included:

Whether the proposed generic contained every required foam component.
Whether the generic’s pH fell within 3.0 to 6.0.
Whether the formulation used a qualifying aliphatic alcohol, fatty alcohol, and surfactant.
Whether a generic method label induced treatment of a claimed disease.
Whether the claims were anticipated or obvious over prior topical foams and corticosteroid formulations.
Whether the claims were enabled across the full corticosteroid genus.
Whether the patent’s isomer-stabilization language was definite and adequately supported.

No current infringement action can preserve exclusivity after expiration. Any settlement agreement entered before expiration would have to be analyzed for its historical impact, including whether it permitted entry before the patent’s reported expiration.

How strong was the patent estate?

The patent estate was commercially useful but technically concentrated. Its strength differed by claim category.

Claim category	Relative strength	Reason
Broad corticosteroid foam method	Moderate	Requires a defined foam system, propellant, and pH range
Betamethasone valerate foam	Moderate to strong historically	Closely aligned with the commercial product
Scalp psoriasis method	Narrow	Limited to a specific disease and patient population
Active-isomer stabilization	Fact-dependent	Depends on proof of isomerization and stabilization
Exact claim 15 formulation	Stronger against close copies	Contains detailed quantitative limitations
Basic betamethasone valerate protection	None from this patent	The patent does not claim the molecule as such

The claims are vulnerable to design-around strategies. A manufacturer could consider a non-aerosol foam, a different propellant, a different surfactant, a pH outside the claimed range, a different buffering system, a different fatty alcohol, or a different corticosteroid. Such changes could affect product performance, stability, aerosol behavior, and regulatory comparability.

The claims also present method-of-use enforcement challenges. Direct infringement requires performance of the claimed treatment method. Induced infringement may depend on the product label, promotional materials, and the approved indications. A generic applicant may seek a skinny label that omits a patented indication, although the practical effect depends on the scope of the approved labeling and the remaining unpatented uses.

Is biosimilar risk relevant to this patent?

No. Betamethasone valerate is a chemically synthesized small molecule, not a biologic. The relevant competitive pathway is an ANDA under Section 505(j) of the Federal Food, Drug, and Cosmetic Act, not a biosimilar application under Section 351(k) of the Public Health Service Act.

The competitive risks are therefore:

Generic betamethasone valerate foam.
Alternative topical corticosteroid foams.
Cream, ointment, lotion, gel, solution, and shampoo formulations.
Nonsteroidal treatments for psoriasis and dermatitis.
Products using different aerosol or foam technologies.

There is no biosimilar interchangeability issue associated with Patent 6,126,920.

What manufacturing and intellectual-property barriers remain after expiration?

Expiration of the patent does not eliminate all barriers to commercial entry. Remaining barriers may include:

Manufacturing know-how

Aerosol foam products require control over:

Propellant filling and pressure.
Valve and actuator performance.
Foam density and collapse time.
Ethanol-water balance.
Fatty alcohol dispersion.
pH and corticosteroid stability.
Microbial control.
Container compatibility.
Scale-up reproducibility.

These factors may be protected through trade secrets rather than patents.

Regulatory requirements

An ANDA applicant must demonstrate pharmaceutical equivalence and bioequivalence or an otherwise acceptable basis for approval. For topical products, FDA may evaluate formulation sameness, active-ingredient concentration, dosage form, delivery characteristics, and comparative performance. The regulatory burden can be meaningful even when no enforceable patent remains.

Non-patent exclusivity and branding

Trademark rights in Luxiq and related trade dress can remain relevant after patent expiry. Trademarks do not block sale of an approved generic under its own name, but they can limit branding and packaging choices.

Later patents

A later patent may cover a specific container, actuator, foam-generation system, manufacturing process, stability profile, or combination product. Such patents must be assessed separately. Patent 6,126,920 does not automatically establish freedom to operate for every later aerosol foam technology.

How does this patent compare with competing topical corticosteroid patent estates?

Patent 6,126,920 is narrower than a composition-of-matter patent but more targeted than a generic vehicle patent. Its commercial value came from the combination of a known corticosteroid with a particular foam delivery platform.

Product or estate type	Primary protection	Relevance to 6,126,920
Betamethasone valerate molecule	Historical molecule and regulatory rights	Separate from the foam patent
Betamethasone valerate cream or ointment	Formulation and use claims	Does not necessarily cover aerosol foam
Corticosteroid aerosol foam	Vehicle, propellant, stability, and use claims	Closest competitive category
Nonsteroidal psoriasis product	Different active ingredient and mechanism	Commercial substitute, not direct patent overlap
Biologic psoriasis therapy	Biologic patents and regulatory exclusivity	No biosimilar relationship to this patent

The patent’s strongest commercial position existed when Luxiq was an approved branded foam with limited direct generic competition. Its blocking value ended when the patent expired.

What generic launch risks exist today?

The patent itself presents no current U.S. launch barrier because it is expired. The remaining launch risks are commercial and regulatory:

FDA approval risk for a topical aerosol foam.
Manufacturing scale-up risk.
Product-performance and stability risk.
Trademark and trade-dress risk.
Possible later patents covering delivery hardware or manufacturing.
Market erosion from lower-cost corticosteroid formulations.
Limited market size relative to development and manufacturing costs.

The likely generic launch scenario is a conventional ANDA product with the same active ingredient, strength, dosage form, and route of administration, supported by a formulation and bioequivalence strategy acceptable to FDA. A Paragraph IV challenge would have been relevant before expiration, but a post-expiration applicant does not need to litigate this patent to obtain approval.

What licensing deals affected the patent?

The patent record alone does not establish the complete chain of commercial licenses, development agreements, or marketing rights associated with Luxiq. Product commercialization changed over time through corporate transactions and dermatology portfolio transfers, but ownership of a marketed product, ownership of the patent, and licensing of manufacturing or distribution rights are separate legal questions.

For diligence purposes, the relevant documents are:

Patent assignment records.
FDA NDA ownership records.
SEC transaction filings.
Product acquisition agreements.
ANDA settlement agreements.
Court orders and consent judgments.

No license should be inferred solely from the appearance of a company name on a product label or from historical marketing arrangements.

Key Takeaways

U.S. Patent 6,126,920 covers topical corticosteroid treatment using a quick-break foam with alcohol, water, fatty alcohol, surfactant, propellant, and buffered pH control.
The principal claims are claims 1 and 4; claims 7, 9, 11, 14, and 15 are the most commercially specific.
Claim 15 closely tracks a 0.12% betamethasone valerate aerosol foam formulation.
The patent was associated with Luxiq betamethasone valerate foam.
The patent expired in 2017, commonly reported as March 13, 2017.
The patent is no longer a current U.S. exclusivity barrier or Paragraph IV launch obstacle.
Generic competition is governed by the ANDA pathway, not the biosimilar pathway.
Remaining barriers are primarily regulatory, manufacturing, trade-secret, trademark, and possible later-patent risks.
Historical litigation and settlement terms require separate review of FDA records, USPTO records, SEC filings, and federal court dockets.

FAQs

Does Patent 6,126,920 cover all betamethasone valerate products?

No. It covers specified topical foam treatment methods and related formulation limitations. Creams, ointments, lotions, gels, and other products may fall outside the claims.

Does a pH outside 3.0 to 6.0 avoid every claim?

No. A pH outside that range may avoid the express pH limitation in claim 1, but claim 4 does not expressly recite that range. Other claim elements and potential equivalents must also be considered.

Can a generic use the same 0.12% betamethasone valerate strength?

Yes, subject to FDA approval and any other enforceable rights. This patent’s expiration removes it as a current barrier.

Is claim 15 limited to Luxiq?

Claim 15 is closely aligned with the listed betamethasone valerate foam formulation, but product identity is determined by claim limitations, not by brand name alone.

Could trade secrets still protect the foam after patent expiration?

Yes. Manufacturing parameters, filling conditions, valve selection, stability controls, and scale-up methods may remain protected as trade secrets even after the patent expires.

References

U.S. Patent No. 6,126,920. (2000). Foamable pharmaceutical compositions. United States Patent and Trademark Office.
U.S. Food and Drug Administration. (n.d.). Approved drug products with therapeutic equivalence evaluations. FDA.
U.S. Food and Drug Administration. (n.d.). Drugs@FDA: FDA-approved drugs. FDA.
U.S. Food and Drug Administration. (n.d.). Orange Book: Approved drug products with therapeutic equivalence evaluations. FDA.
U.S. Patent and Trademark Office. (n.d.). Patent term adjustment and patent term extension information. USPTO.
Federal Food, Drug, and Cosmetic Act, 21 U.S.C. § 355(j).
Public Health Service Act, 42 U.S.C. § 262(k).

Foriegn Application Priority Data
Foreign Country	Foreign Patent Number	Foreign Patent Date
United Kingdom	9504265	Mar 03, 1995

PCT Information
PCT Filed	March 01, 1996	PCT Application Number:	PCT/GB96/00490
PCT Publication Date:	September 12, 1996	PCT Publication Number:	WO96/27376

Country	Patent Number	Estimated Expiration	Supplementary Protection Certificate	SPC Country	SPC Expiration
Austria	253367	⤷ Start Trial
Australia	4885196	⤷ Start Trial
Australia	709320	⤷ Start Trial
>Country	>Patent Number	>Estimated Expiration	>Supplementary Protection Certificate	>SPC Country	>SPC Expiration

Details for Patent: 6,126,920

Summary for Patent: 6,126,920